Day One Biopharmaceuticals, Inc vs UnitedHealth Group Incorporated — Stock Comparison
Day One Biopharmaceuticals, Inc (DAWN) and UnitedHealth Group Incorporated (UNH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
UnitedHealth Group Incorporated clearly outscores Day One Biopharmaceuticals, Inc on Q·Score (6.1 vs 4.5 out of 10), led by Sentiment (8.1 vs 2.5) and Quality (5.9 vs 0.5). Day One Biopharmaceuticals, Inc scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for UNH (+2.2%) than for DAWN (-0.1%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-68% margin).
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
Fundamentals
Frequently Asked Questions
DAWN vs UNH: which stock scores better overall?
Based on Q·Score, UnitedHealth Group Incorporated (UNH) scores 6.1/10 versus Day One Biopharmaceuticals, Inc (DAWN) at 4.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: DAWN or UNH?
Day One Biopharmaceuticals, Inc (DAWN) scores higher on Growth (7.3/10 vs 5.1/10). Day One Biopharmaceuticals, Inc reports revenue growth (83.9% YoY) while UnitedHealth Group Incorporated reports (2.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is DAWN or UNH more attractively valued?
UnitedHealth Group Incorporated (UNH) scores higher on Valuation (6.5/10 vs 3.7/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about DAWN vs UNH?
There are 6 analysts covering DAWN with a consensus price target of $21.50, and 26 analysts covering UNH with a consensus target of $409.77. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: DAWN or UNH?
UnitedHealth Group Incorporated (UNH) scores higher on Quality (5.9/10 vs 0.5/10). Net profit margin: DAWN at -67.8%, UNH at 2.7%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: DAWN or UNH?
Day One Biopharmaceuticals, Inc (DAWN) scores higher on Financial Health (9.2/10 vs 5.3/10). Market beta: DAWN at -1.75, UNH at 0.65. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of DAWN and UNH?
Day One Biopharmaceuticals, Inc (DAWN) has a market capitalisation of $2.2B, while UnitedHealth Group Incorporated (UNH) has a market cap of $364.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →